TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00907166
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
Study: NCT00907166
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
Study: NCT00820222
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral medication; daily dose taken once a day
Study: NCT00820222
Drug: trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
Study: NCT00437255
Drug: Clobetasol Propionate, 0.05%
Normalized name: Clobetasol Propionate, 0.05% topical gel
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical, twice daily for 4 weeks
Study: NCT00437255
Drug: Calcipotriene and betamethasone dipropionate ointment
Normalized name: Calcipotriene And Betamethasone Dipropionate Ointment
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical, once daily
Study: NCT04199143
Drug: Nitrous Oxide-Oxygen
Normalized name: nitrous oxide-oxygen
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The medical product used in this study is a gas for common medical use in various domains including anesthesic, consisting in the equimolar mixture of nitrous oxide and oxygen. Subjects will receive a mixture of 50% N2O / 50% O2 for 1 hour.
Study: NCT03327558
Drug: APRISO 375 mg extended-release capsules
Normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 375 mg extended-release capsules
Study: NCT01300260
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT01300260
Drug: Glucose
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT01300260
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT04678791
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.
Study: NCT04678791
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
Study: NCT01720238
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg qd
Study: NCT01720238
Drug: Lamivudine plus Adefovir Dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
Study: NCT03903939
Drug: Iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuously infusion for 72 hours 1 ng/kg/min
Study: NCT00095173
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
Study: NCT00095173
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing \< 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing \> 100 kg, monthly
Study: NCT01563172
Drug: Sodium fluoride / silica and carbopol, 0.5g
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol
Study: NCT01563172
Drug: Sodium fluoride / silica and carbopol, 1.5g
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
Study: NCT01563172
Drug: Sodium fluoride / silica and carbopol, 1.5g
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
Study: NCT05551507
Drug: IN10018 in combination with PLD
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer
Study: NCT04132674
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taking one oral tablet of B/F/TAF once-daily for 72 weeks
Study: NCT00908466
Drug: Sirolimus (rapamycin)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
Study: NCT00908466
Drug: Sirolimus (rapamycin)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
Study: NCT01919216
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01046214
Drug: Bupropion HCl
Normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
Study: NCT01046214
Drug: Bupropion HCl
Normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
Study: NCT02376803
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morning vs Evening administration
Study: NCT02854748
Drug: Empagliflozin 25mg
Normalized name: EMPAGLIFLOZIN 25MG TAB
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 25 mg QD for 5 days
Study: NCT02854748
Drug: Lobeglitazone 0.5mg
DrugBank: Lobeglitazone (DB09198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone 0.5mg QD for 5 days
Study: NCT02854748
Drug: Empagliflozin 25mg/Lobeglitazone 0.5mg
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
Study: NCT02945241
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous
Study: NCT02199964
Drug: Cyclosporin 0.05% emulsion
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy for dry eye
Study: NCT01664637
Drug: 10 mg TZP-102
Normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One oval-shaped, opaque-white, hard gelatin capsule containing active ingredient will be taken orally three times a day for 12 weeks
Study: NCT00799890
Drug: Sunphenon EGCG
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-800mg (1-4 capsules)
Study: NCT02702128
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours
Study: NCT02702128
Drug: saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
Study: NCT00995995
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone
Study: NCT03624127
Drug: BMS-986165
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT03624127
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT03939702
Drug: BMS-986177
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: An orally administered anticoagulant to prevent and treat thromboembolic events
Study: NCT01416636
Drug: Treprostinil sodium
Normalized name: Treprostinil Sodium
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03856411
Drug: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
Normalized name: toripalimab Injection
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.
Study: NCT02301169
Drug: Administration of T4P1001 capsules
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This treatment is given as add on therapy to patients' regular analgesic
Study: NCT01881568
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
Study: NCT01881568
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
Study: NCT00218023
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase I.
Study: NCT00218023
Drug: Naltrexone HCl
Normalized name: naltrexone HCl
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase I.
Study: NCT02655614
Drug: GDC-0134
Normalized name: GDC-0134
DrugBank: GDC-0134 (DB17079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.
Study: NCT02655614
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole 20 mg twice daily orally
Study: NCT02655614
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg of liquid formulation of midazolam orally
Study: NCT02993055
Drug: Ulimorelin
Normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01829217
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03687606
Drug: Human Chorionic Gonadotropin
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
Study: NCT03687606
Drug: human menopausal gonadotropin
Normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White freeze-dried cake or powder with specification of 75IU.
Study: NCT00961194
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup.
Study: NCT03576716
Drug: D6-25-hydroxyvitamin D3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
Study: NCT02249182
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
Study: NCT03286816
Drug: SodiumChloride
Normalized name: Dextrose 2.5% and 0.45% SodiumChloride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03286816
Drug: Sodium Lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03505528
Drug: Nanoparticle albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abraxane is administered intravenous at a constant dose of 100mg/m2
Study: NCT03505528
Drug: Phenelzine Sulfate
Normalized name: Phenelzine Sulfate
DrugBank: Phenelzine (DB00780)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nardil is administered orally from a starting dose of 15mg/d to a maximum of 90mg/d
Study: NCT01769820
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: studies 1\&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
Study: NCT02841241
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol infusion
Study: NCT01092663
Drug: Colesevelam HCl
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
Study: NCT01092663
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
Study: NCT00967096
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin for Bone marrow transplant patients
Study: NCT04328272
Drug: Hydroxychloroquine 200 Mg Oral Tablet
Normalized name: hydroxychloroquine 200 mg oral tablet
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine administered orally with water
Study: NCT00697710
Drug: 50 mg S-777469
Normalized name: HYMETELLOSE (50 MPA.S)
DrugBank: S-777469 (DB16321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-777469, 50 mg BID
Study: NCT00697710
Drug: 200 mg S-777469
Normalized name: S-adenosylmethionine 200 MG
DrugBank: S-777469 (DB16321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-777469, 200 mg BID
Study: NCT00697710
Drug: 800 mg S-777469
Normalized name: S-777469
DrugBank: S-777469 (DB16321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-777469, 800 mg BID
Study: NCT01719614
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.
Study: NCT04617015
Drug: Ipratropium Bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.
Study: NCT01710098
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: subcutaneous injection
Study: NCT03067623
Drug: PRP
Normalized name: PRP
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP intrauterine infusion
Study: NCT01719614
Drug: Rilpivirine
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.
Study: NCT02113332
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02878837
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02878837
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01431391
Drug: leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45.0 mg depot injection, 2 doses 6 months apart
Study: NCT00158691
Drug: Ethyol
Normalized name: Ethyol
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01960153
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks
Study: NCT01887847
Drug: Nicotine (Pharmaceutical Productions Inc.)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
Study: NCT01887847
Drug: Nicotine (Pharmaceutical Productions Inc.)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
Study: NCT01549977
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat tablets
Study: NCT03181633
Drug: ACH-0144471
Normalized name: ACH-0144471
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACH-0144471 will be administered to all participants enrolled in the study.
Study: NCT03043651
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sustained-release oral tablets for TID administration
Study: NCT02186145
Drug: Association of metronidazole; nystatin and dexamethasone
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02186145
Drug: Flagyl
Normalized name: Flagyl
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal cream of metronidazole and nystatin
Study: NCT00017407
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00017407
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02253784
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02253784
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02020408
Drug: [11C]raclopride
DrugBank: Raclopride (DB12518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.\[11C\]raclopride -The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
Study: NCT02020408
Drug: amphetamine
Normalized name: Amphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
Study: NCT01248637
Drug: Pimonidazole hydrochloride
Normalized name: Pimonidazole
DrugBank: Pimonidazole (DB12485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 \<= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
Study: NCT02428205
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant will receive Propranolol prior to each EIBI session
Study: NCT00006433
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01630889
Drug: Roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Oral capsule
Study: NCT00235287
Drug: Candesartan and enalapril
Normalized name: candesartan and diuretics
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
Study: NCT00235287
Drug: candesartan and enalapril
Normalized name: candesartan and diuretics
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
Study: NCT00235287
Drug: candesartan and enalapril
Normalized name: candesartan and diuretics
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.